ATE239462T1 - Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus - Google Patents

Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus

Info

Publication number
ATE239462T1
ATE239462T1 AT96936418T AT96936418T ATE239462T1 AT E239462 T1 ATE239462 T1 AT E239462T1 AT 96936418 T AT96936418 T AT 96936418T AT 96936418 T AT96936418 T AT 96936418T AT E239462 T1 ATE239462 T1 AT E239462T1
Authority
AT
Austria
Prior art keywords
creatine
compounds
analogues
act
glucose metabolism
Prior art date
Application number
AT96936418T
Other languages
English (en)
Inventor
Rima Kaddurah-Daouk
Beverly A Teicher
Original Assignee
Avicena Group Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avicena Group Inc, Dana Farber Cancer Inst Inc filed Critical Avicena Group Inc
Application granted granted Critical
Publication of ATE239462T1 publication Critical patent/ATE239462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96936418T 1995-10-11 1996-10-11 Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus ATE239462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54089495A 1995-10-11 1995-10-11
PCT/US1996/016365 WO1997013507A1 (en) 1995-10-11 1996-10-11 Use of creatine analogues for the treatment of disorders of glucose metabolism

Publications (1)

Publication Number Publication Date
ATE239462T1 true ATE239462T1 (de) 2003-05-15

Family

ID=24157358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96936418T ATE239462T1 (de) 1995-10-11 1996-10-11 Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus

Country Status (8)

Country Link
US (3) US6075031A (de)
EP (1) EP0854712B1 (de)
JP (1) JPH11513671A (de)
AT (1) ATE239462T1 (de)
AU (1) AU721190B2 (de)
CA (1) CA2231632C (de)
DE (1) DE69628025T2 (de)
WO (1) WO1997013507A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2268696T3 (es) * 1994-11-08 2007-03-16 Avicena Group, Inc. Uso de creatina o analogos de creatina para el tratamiento de la enfermedad de huntigton, enfermedad de parkinson y esclerosis lateral amiotrofica.
US6274161B1 (en) * 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
US8128955B2 (en) * 1996-05-31 2012-03-06 The Original Creatine Patent Company Food compositions containing creatine
US7150880B2 (en) * 1996-05-31 2006-12-19 The Original Creatine Patent Co. Ltd. Compositions containing creatine and creatinine and a methyl xanthine
US6524611B2 (en) 1996-05-31 2003-02-25 The Howard Foundation Compositions containing creatine and creatinine
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
DK1100488T3 (da) * 1998-07-28 2003-08-11 Synthes Ag Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6444695B1 (en) 2000-09-21 2002-09-03 The Regents Of The University Of California Inhibition of thrombin-induced platelet aggregation by creatine kinase inhibitors
US6903136B2 (en) * 2002-04-22 2005-06-07 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US20040126366A1 (en) * 2002-06-04 2004-07-01 Rima Kaddurah-Daouk Methods of treating cognitive dysfunction by modulating brain energy metabolism
US20120245211A1 (en) * 2002-06-04 2012-09-27 Children's Hospital Medical Center Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
JP4709739B2 (ja) 2003-02-28 2011-06-22 イーエルシー マネージメント エルエルシー 毛髪成長の増進方法
GB0411985D0 (en) * 2004-05-28 2004-06-30 Howard Foundation Holdings Ltd Food compositions containing creatine
DE102004036047A1 (de) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologisch aktive Zusammensetzung
US20070292403A1 (en) * 2006-05-11 2007-12-20 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US20070281995A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine analog prodrugs, compositions and uses thereof
WO2007146088A1 (en) * 2006-06-06 2007-12-21 Xenoport, Inc. Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof
US7683043B2 (en) * 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
US20070281983A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine analog prodrugs, compositions and uses thereof
US20070281909A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine phosphate prodrugs, compositions and uses thereof
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
ES2615204T3 (es) 2009-04-06 2017-06-05 Crearene Ltd. Soluciones para la hemodiálisis y diálisis peritoneal que comprenden uno o más compuestos de creatina
EP2701509A4 (de) * 2011-04-29 2015-06-17 Catabasis Pharmaceuticals Inc Fettsäure-guanidin- und salicylat-guanidin-derivate und ihre verwendungen
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
ES2885451T3 (es) 2014-04-30 2021-12-13 Inspirna Inc Inhibidores del transporte de creatina y usos de los mismos
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
JP2018511582A (ja) * 2015-03-10 2018-04-26 ルモス ファーマ， インコーポレイテッド シクロクレアチン微細懸濁物
JP7433226B2 (ja) 2017-12-01 2024-02-19 ウルトラジェニクス ファーマシューティカル インク． クレアチンプロドラッグ、組成物及びその使用方法
JP7653165B2 (ja) * 2019-11-10 2025-03-28 プロ－アル・メディコ－テクノロジーズ・インコーポレイテッド 新規な製剤および方法
WO2021119316A1 (en) 2019-12-11 2021-06-17 Rgenix, Inc. Methods of treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA891509A (en) * 1972-01-25 Beecham Group Limited Esters and amides of guanidine aliphatic acids
GB1153424A (en) * 1965-04-15 1969-05-29 Horlicks Ltd Pharmaceutical Compositions
GB1195199A (en) * 1966-11-25 1970-06-17 Horlicks Pharmaceuticals Ltd Improvements in Compositions comprising Insulin.
GB1195200A (en) * 1967-02-07 1970-06-17 Horlicks Pharmaceuticals Ltd Pharmaceutical Compositions.
GB1552179A (en) * 1976-11-02 1979-09-12 Beecham Group Ltd Pharmaceutical compositions for treating hyperglycaemia
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
US5321030A (en) * 1989-02-14 1994-06-14 Amira, Inc. Creatine analogs having antiviral activity
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
WO1990009192A1 (en) * 1989-02-14 1990-08-23 Massachusetts Institute Of Technology Inhibiting transformation of cells having elevated purine metabolic enzyme activity
WO1991012799A1 (en) * 1990-02-28 1991-09-05 The Upjohn Company Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
US5091404A (en) * 1990-10-05 1992-02-25 Elgebaly Salwa A Method for restoring functionality in muscle tissue
AU6165894A (en) * 1993-01-28 1994-08-15 Trustees Of The University Of Pennsylvania, The Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth

Also Published As

Publication number Publication date
AU721190B2 (en) 2000-06-29
CA2231632C (en) 2004-01-20
DE69628025D1 (de) 2003-06-12
JPH11513671A (ja) 1999-11-24
CA2231632A1 (en) 1997-04-17
DE69628025T2 (de) 2004-04-01
AU7442796A (en) 1997-04-30
EP0854712A1 (de) 1998-07-29
WO1997013507A1 (en) 1997-04-17
US20030232793A1 (en) 2003-12-18
US20050256134A1 (en) 2005-11-17
US6075031A (en) 2000-06-13
EP0854712B1 (de) 2003-05-07

Similar Documents

Publication Publication Date Title
ATE239462T1 (de) Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus
IL132598A0 (en) Method for purifying lactic acid
ATE209921T1 (de) Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust
ES2191066T3 (es) Preparacion enantioselectiva de sulfoxidos farmaceuticamente activos por biooxidacion.
BR9814984A (pt) Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio
ATE409466T1 (de) Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
ATE332127T1 (de) Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
ATE455547T1 (de) Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
EP1143955A3 (de) Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
EP1005349A4 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
BR9508295A (pt) Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina
NZ510920A (en) Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
Lumeng et al. Suppression of the mitochondrial oxidation of (-)-palmitylcarnitine by the malate-aspartate and alpha-glycerophosphate shuttles.
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
CA2116535A1 (en) A Method for Treatment of Patients with Chronic Liver Disease
Arrio-Dupont An example of substrate channeling between co‐immobilized enzymes Coupled activity of myosin ATPase and creatine kinase bound to frog heart myofilaments
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
AU4530796A (en) Treating disorders characterised by excessive cell proliferation with sclareolide
Wellner et al. Evidence for an intermediate in the oxidation of reduced L-amino acid oxidase by molecular oxygen
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
Micheli et al. Effect of non-steroidal anti-inflammatory drugs on glutathione levels in various organs of rat
Vandenheede et al. The ATP, Mg-dependent phosphatase: role of Mg ions in the expression of the phosphorylase phosphatase activity
ATE180478T1 (de) Verwendung von substituierten 6-amino-4h-pyranen
EGASHIRA et al. Changes in MAO Activities in Several Organs of Rats after Administration of/-Thyroxine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties